Genetic Testing of 18 Hereditary Cancer

This hereditary genetic testing can provide risk assessment in high-risk groups with a family history by detecting hereditary breast cancer gene mutations in the entire coding region and splice region of 64 genes associated with 18 hereditary tumors at one time.

Hereditary testing of 18 Hereditary Cancer Applicable Population
Patients with tumors, especially those with tumors diagnosed at an unusually young age, or those with tumors that occur on both sides of paired organs (eg, kidneys, breasts).

People with a family history of cancer, especially if multiple close relatives have the same type of cancer (eg, mother, daughter, sister with breast cancer).

Patients with birth defects associated with hereditary tumor syndromes, such as certain benign skin abnormalities or skeletal deformities.

If you are looking for a reliable IVD company, don't hesitate to contact us!

For more about microfluidic platform, please feel free to contact us!

CapitalBio Technology Co., Ltd. (abbreviated “CapitalBio”) is the industrialization platform of the CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. CapitalBio has always adhered to independent innovation and achievement transformation and has a complete industrial chain integrating R&D, production, sales, and thrid-party independent medical laboratory services; and responds to the national policy of “prevention first.” The health policy integrates modern medicine and traditional Chinese medicine to form a large health industry section that includes health products, health management, medical rehabilitation, and big data.